JP5701058B2 - 髄膜炎菌ワクチン処方物 - Google Patents

髄膜炎菌ワクチン処方物 Download PDF

Info

Publication number
JP5701058B2
JP5701058B2 JP2010529472A JP2010529472A JP5701058B2 JP 5701058 B2 JP5701058 B2 JP 5701058B2 JP 2010529472 A JP2010529472 A JP 2010529472A JP 2010529472 A JP2010529472 A JP 2010529472A JP 5701058 B2 JP5701058 B2 JP 5701058B2
Authority
JP
Japan
Prior art keywords
men
lyophilized
composition
serogroup
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010529472A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500662A5 (https=
JP2011500662A (ja
Inventor
マリオ コントールニ，
マリオ コントールニ，
ジーナ カザズ，
ジーナ カザズ，
ディレク オヘーガン，
ディレク オヘーガン，
シン，　マンモハン
マンモハン シン，
ミルドレッド ウゴゾーリ，
ミルドレッド ウゴゾーリ，
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2011500662A publication Critical patent/JP2011500662A/ja
Publication of JP2011500662A5 publication Critical patent/JP2011500662A5/ja
Application granted granted Critical
Publication of JP5701058B2 publication Critical patent/JP5701058B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2010529472A 2007-10-19 2008-10-17 髄膜炎菌ワクチン処方物 Expired - Fee Related JP5701058B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99959007P 2007-10-19 2007-10-19
US60/999,590 2007-10-19
PCT/IB2008/003283 WO2009050586A1 (en) 2007-10-19 2008-10-17 Meningococcal vaccine formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013157634A Division JP5925736B2 (ja) 2007-10-19 2013-07-30 髄膜炎菌ワクチン処方物

Publications (3)

Publication Number Publication Date
JP2011500662A JP2011500662A (ja) 2011-01-06
JP2011500662A5 JP2011500662A5 (https=) 2011-12-01
JP5701058B2 true JP5701058B2 (ja) 2015-04-15

Family

ID=40428348

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010529472A Expired - Fee Related JP5701058B2 (ja) 2007-10-19 2008-10-17 髄膜炎菌ワクチン処方物
JP2013157634A Expired - Fee Related JP5925736B2 (ja) 2007-10-19 2013-07-30 髄膜炎菌ワクチン処方物
JP2015226282A Withdrawn JP2016029108A (ja) 2007-10-19 2015-11-19 髄膜炎菌ワクチン処方物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013157634A Expired - Fee Related JP5925736B2 (ja) 2007-10-19 2013-07-30 髄膜炎菌ワクチン処方物
JP2015226282A Withdrawn JP2016029108A (ja) 2007-10-19 2015-11-19 髄膜炎菌ワクチン処方物

Country Status (20)

Country Link
US (2) US20100285069A1 (https=)
EP (2) EP2200642B1 (https=)
JP (3) JP5701058B2 (https=)
CN (1) CN101951949B (https=)
AT (1) ATE553774T1 (https=)
AU (1) AU2008313424B2 (https=)
BR (2) BR122016015627A2 (https=)
CA (2) CA2702871A1 (https=)
CO (1) CO6270339A2 (https=)
CY (1) CY1112908T1 (https=)
DK (1) DK2200642T3 (https=)
ES (1) ES2383231T3 (https=)
HR (1) HRP20120433T1 (https=)
MX (2) MX2010004271A (https=)
NZ (1) NZ584683A (https=)
PL (1) PL2200642T3 (https=)
PT (1) PT2200642E (https=)
RU (2) RU2498815C2 (https=)
SI (1) SI2200642T1 (https=)
WO (1) WO2009050586A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
ES2555786T3 (es) * 2007-06-04 2016-01-08 Glaxosmithkline Biologicals Sa Formulación de vacunas contra la meningitis
WO2010070453A2 (en) * 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
AU2011295853A1 (en) 2010-09-01 2013-04-04 Irm Llc Adsorption of immunopotentiators to insoluble metal salts
AU2011300409B2 (en) 2010-09-10 2015-03-26 Wyeth Llc Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
IN2012MU00206A (https=) * 2012-01-20 2013-08-09
SI2822947T1 (sl) 2012-03-07 2016-10-28 Glaxosmithkline Biologicals S.A. Argininske soli TLR7 agonista
MX372965B (es) 2012-03-08 2020-04-01 Glaxosmithkline Biologicals Sa Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
WO2014016152A1 (en) 2012-07-27 2014-01-30 Institut National De La Sante Et De La Recherche Medicale Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
BR112019003992A2 (pt) 2016-09-02 2019-05-28 Sanofi Pasteur Inc vacina contra neisseria meningitidis
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR20200077538A (ko) * 2017-10-25 2020-06-30 머크 샤프 앤드 돔 코포레이션 아주반트 첨가된 백신
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US5204098A (en) 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
KR920703114A (ko) 1989-07-14 1992-12-17 원본미기재 접합체 백신을 위한 시토킨 및 호르몬 운반체
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
IL101007A (en) 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
PL175595B1 (pl) 1992-08-31 1999-01-29 North American Vaccine Inc Antygenowy/immunogenny koniugat do wytwarzania szczepionki przeciwko infekcji N.meningitidis, sposób wytwarzania antygenowego/immunogennego koniugatu oraz szczepionka przeciwko infekcji N.meningitidis
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
WO1998053851A1 (en) 1997-05-28 1998-12-03 University Of Iowa Research Foundation Laft mutants of pathogenic gram-negative bacteria
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
ES2301181T3 (es) 1997-08-21 2008-06-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Mutantes nuevos de bacterias mucosas gram negativas y su aplicacion en vacunas.
CA2671261A1 (en) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
EP1047784B2 (en) 1998-01-14 2015-03-18 Novartis Vaccines and Diagnostics S.r.l. Neissera meningitidis antigens
CZ298364B6 (cs) * 1998-02-05 2007-09-05 Smithkline Beecham Biologicals S. A. Deriváty antigenu asociovaných s nádory z MAGE rodiny a sekvence nukleových kyselin kodující tyto deriváty, jejich použití pro prípravu fúzních proteinu a prostredku pro vakcinaci
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
EP2261338A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
EP1741443B1 (en) * 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
WO1999061053A1 (en) * 1998-05-29 1999-12-02 Chiron Corporation Combination meningitidis b/c vaccines
DE69941574D1 (de) 1998-08-19 2009-12-03 Baxter Healthcare Sa Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid
BR9914374A (pt) 1998-10-09 2002-09-17 Chiron Corp Sequências genÈmicas de neisseria e métodos para seu uso
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
AU762369B2 (en) 1998-11-03 2003-06-26 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur LPS with reduced toxicity from genetically modified gram negative bacteria
AU1626199A (en) 1998-12-04 2000-06-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A vi-repa conjugate vaccine for immunization against salmonella typhi
ATE459373T1 (de) 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
NZ521531A (en) 2000-02-28 2005-12-23 Chiron S Heterologous expression of neisserial proteins
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
ES2519440T3 (es) 2000-07-27 2014-11-07 Children's Hospital & Research Center At Oakland Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
SI21352A (sl) 2001-01-23 2004-06-30 Aventis Pasteur Multivalentno meningokokno cepivo iz konjugata polisaharida-proteina
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
ES2616180T3 (es) 2002-03-26 2017-06-09 Glaxosmithkline Biologicals Sa Sacáridos modificados con estabilidad mejorada en agua para su uso como medicamento
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
US20060057160A1 (en) 2002-08-02 2006-03-16 Ralph Biemans Vaccine composition
GB0218821D0 (en) * 2002-08-13 2002-09-18 Glaxosmithkline Biolog Sa Novel compositions
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CA2501476A1 (en) * 2002-10-07 2004-04-22 Chiron Corporation Hiv vaccine formulations
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
EP1562982B1 (en) * 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2172213B1 (en) * 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
NZ546430A (en) * 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
JP5173194B2 (ja) * 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
KR20110132416A (ko) 2004-04-05 2011-12-07 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
EP1812056B1 (en) * 2004-11-15 2013-08-07 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant
WO2006081259A2 (en) 2005-01-27 2006-08-03 Children's Hospital & Research Center At Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
AR054020A1 (es) 2005-03-23 2007-05-30 Glaxosmithkline Biolog Sa Nuevo uso
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8156755B2 (en) * 2005-06-03 2012-04-17 Intervet International B.V. Refrigerator for storing vials and cartridge for use in the same
PE20110072A1 (es) 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
KR101515078B1 (ko) 2005-12-22 2015-04-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
US8431160B2 (en) * 2006-02-24 2013-04-30 Novartis Ag Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
ES2555786T3 (es) * 2007-06-04 2016-01-08 Glaxosmithkline Biologicals Sa Formulación de vacunas contra la meningitis

Also Published As

Publication number Publication date
PL2200642T3 (pl) 2012-09-28
RU2013133864A (ru) 2015-01-27
BR122016015627A2 (pt) 2018-10-30
JP5925736B2 (ja) 2016-05-25
WO2009050586A1 (en) 2009-04-23
CY1112908T1 (el) 2016-04-13
NZ584683A (en) 2012-05-25
EP2462949A3 (en) 2012-09-05
CN101951949B (zh) 2013-10-02
ES2383231T3 (es) 2012-06-19
DK2200642T3 (da) 2012-07-16
BRPI0818545A2 (pt) 2017-07-04
ATE553774T1 (de) 2012-05-15
RU2498815C2 (ru) 2013-11-20
CN101951949A (zh) 2011-01-19
EP2200642A1 (en) 2010-06-30
MX340096B (es) 2016-06-27
PT2200642E (pt) 2012-05-30
EP2462949A2 (en) 2012-06-13
JP2013216704A (ja) 2013-10-24
AU2008313424A1 (en) 2009-04-23
CA2702871A1 (en) 2009-04-23
US20160228529A1 (en) 2016-08-11
EP2200642B1 (en) 2012-04-18
JP2011500662A (ja) 2011-01-06
US20100285069A1 (en) 2010-11-11
CA2925217A1 (en) 2009-04-23
RU2010119947A (ru) 2011-11-27
SI2200642T1 (sl) 2012-06-29
CO6270339A2 (es) 2011-04-20
JP2016029108A (ja) 2016-03-03
HRP20120433T1 (en) 2012-07-31
AU2008313424B2 (en) 2014-05-22
MX2010004271A (es) 2010-05-03

Similar Documents

Publication Publication Date Title
JP5925736B2 (ja) 髄膜炎菌ワクチン処方物
JP5637848B2 (ja) 髄膜炎ワクチンの製剤化
JP6191082B2 (ja) より低用量の抗原および／またはアジュバントを有する混合ワクチン
JP5806204B2 (ja) 肺炎球菌血清型１４の糖を含む組み合わせ
JP6324961B2 (ja) 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
US20130071422A1 (en) Adjuvanted vaccines for serogroup b meningococcus
JP2010529103A5 (https=)
JP2015028081A (ja) 髄膜炎菌ｈ因子結合タンパク質および肺炎球菌糖結合体の組み合わせ
JP2016502994A (ja) ジフテリア及び／又は破傷風から防御するためのコンジュゲート
AU2013204315B2 (en) Meningococcal vaccine formulations
AU2013202593A1 (en) Adjuvanted vaccines for serogroup B meningococcus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140320

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150217

R150 Certificate of patent or registration of utility model

Ref document number: 5701058

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees